Neurogene Inc.
NGNE · Price history
Price at last available close
$26.99
−$1.49 (-5.23%) 1M
2026-10-27
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Neurogene Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
How they make money
Neurogene is a clinical-stage biotechnology company that does not currently generate revenue from product sales. Its business model relies on research and development of genetic medicines, funded through capital raises and equity financing, as it works toward regulatory approval and commercialization of its gene therapy candidates.
Products & services
The company is developing NGN-401, a gene therapy candidate for Rett syndrome that utilizes proprietary EXACT transgene regulation technology to control protein expression levels.
Brands & revenue mix
Lead gene therapy candidate for the treatment of Rett syndrome.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
- Patients with rare neurological diseasesSource
Customer concentration
No quantified customer-concentration disclosure is available in the current saved research.
Suppliers, materials & equipment
- Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of clinical trial materials; specific supplier names are unnamed.Source
Business relationships & partnerships
- University of Edinburgh — A master collaboration and license agreement for research and development projects and exclusive rights to patents and know-how related to EXACT technology and MECP2 cassettes.Source
Competitors
- Gene therapy developers — The company faces competition from other biotechnology and pharmaceutical companies developing gene therapies for Rett syndrome and other rare neurological disorders.Source
Strengths
Sources
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
33
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
47
Weak
Financial Strength
65
Business Quality / Moat
68
Management
40
Growth Quality
0
Risk / Durability
22
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
39
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
47/100
Building Historical Record
Model Score 47/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
- •Balance-sheet / debt profile scores strongly
- •Debt service risk
- •Valuation is a weaker part of the current profile
- •Asset quality is a weaker factor
Company-specific research
Questions worth answering for NGNE
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •How long can NGNE fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •How is NGNE likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •What specifically needs to improve for NGNE to reach sustainable profitability?
- •What future growth or profitability would be needed to justify NGNE's current valuation?
- •What does the current none warning mean for the reliability or interpretation of NGNE's score?
Essential Investment Snapshot
Wall Street Score
33
Opportunity Score
39
Market Cap
$426.5M
P/E Ratio
-4.2
EPS
$-5.51
52-Week High
$43.66
52-Week Low
$15.93
Beta
2.09
Analyst Target
$70.00
Shares Outstanding
21.2M
Total Revenue
$0
Total Debt
$8.3M
Dividend
No current dividend
Liquidation Value / Share
$10.26
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Neutral / mixed momentum
Extreme movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for NGNE
Detected from reported data — verify before acting.Debt service risk
Interest coverage is low (~-20641.6x). Earnings may be strained to cover interest expense.
Community Sentiment
0 active · 0 total callsNo personal call yet on NGNE.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Proprietary EXACT transgene regulation technology.
- +Breakthrough Therapy designation for NGN-401.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Biotechnology industry.
- −History of operating losses and expectation of future losses.
- −Dependence on third-party manufacturers for clinical supply.
- −Uncertainty of clinical trial success and regulatory approval.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
4 historical score records availablePrevious Score
32
Oct 8, 2026
Change
+0.4
points
Current Score
33
Oct 23, 2026
Category Changes
NGNE increased 0.4 points because Asset improved by 3 points.
Positive Contributors
- + Asset improved by 3 points
Projected Score
Projected Score
37
Projected Change
+4.7 points
Preliminary comparable-period financial changes suggest improvement of approximately 4.7 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$26.99
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Large reported revenue change: -96.3%
Revenue changed sharply from 2018 to 2024. This can reflect a real business change, acquisition, divestiture, discontinued operations, restatement, or reporting-basis change. Compare the underlying filing before treating it as normal growth or decline.
TTM may combine quarters from before and after the event, so its trend can also be distorted.
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $0.00 | $925K | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | — | $3.2M | $3.2M | $3.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | — | -$3.2M | -$2.3M | -$3.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | — | $75.0M | $60.9M | $44.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | — | $25.1M | $22.6M | $11.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | — | $100.0M | $80.3M | $52.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | — | -$87.3M | -$71.9M | -$33.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | — | -$103.2M | -$82.6M | -$55.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | — | $5K | $12K | $12K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | — | -$90.4M | -$75.1M | -$36.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | — | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | — | -$90.4M | -$75.1M | -$36.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | — | $-4.24 | $-4.28 | $-2.83 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 22.55M | 21.17M | 17.57M | 12.82M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 22.55M | 21.17M | 17.57M | 12.82M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$0
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$1.53
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-35.1%
Cash Change
+91.3%
Margin Change
Not available
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Cash position grew
- Debt reduced
Potential Score Impact
Positive indicators included EPS growth, cash levels, debt levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
EPS increased 45.7%. Cash increased 91.3%. Total debt declined 35.1%.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
4 historical recordsHistorical Score Chart
3 of 4 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyNews
Intellia Therapeutics (NASDAQ:NTLA) and Neurogene (NASDAQ:NGNE) Critical Survey
Neurogene Announces Upcoming Presentations Highlighting Key Differentiators of NGN-401 for Rett Syndrome at the ESGCT 33rd Annual Congress
Neurogene (NASDAQ:NGNE) Sees Large Volume Increase – Should You Buy?
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rumor Mill · NGNE
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial